CGH
PRCT icon

Crossmark Global Holdings’s Procept Biorobotics PRCT Stock Holding History

Crossmark Global Holdings’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,525
Closed -$338K – 1337
2024
Q2 		$338K Sell
5,525
-3,583
-39% -$213K 0.01% 1008
2024
Q1 		$450K Sell
9,108
-2,980
-25% -$142K 0.01% 918
2023
Q4 		$507K Buy
12,088
+358
+3% +$12.2K 0.01% 841
2023
Q3 		$381K Buy
11,730
+2,349
+25% +$80.1K 0.01% 915
2023
Q2 		$331K Buy
9,381
+33
+0.4% +$1.09K 0.01% 1026
2023
Q1 		$265K Buy
9,348
+114
+1% +$4.02K 0.01% 1095
2022
Q4 		$384K Buy
9,234
+2,535
+38% +$109K 0.01% 911
2022
Q3 		$278K Buy
6,699
+149
+2% +$5.94K 0.01% 1026
2022
Q2 		$214K Buy
+6,550
New +$238K 0.01% 1185

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Crossmark Global Holdings's PRCT Position: Q3 2024 in Review

Crossmark Global Holdings sold out of Procept Biorobotics (PRCT) in Q3 2024, closing a stake of 5,525 shares — an estimated $338K sold.

Crossmark Global Holdings first reported a position in PRCT in Q2 2022 and held it in 9 quarters. The position peaked at $507K in Q4 2023. 250 funds tracked by Wall St. Rank hold PRCT as of Q3 2024.

  • Crossmark Global Holdings reported no remaining Procept Biorobotics position as of Q3 2024 after selling out during the quarter.
  • Crossmark Global Holdings sold 5,525 Procept Biorobotics shares in Q3 2024, an estimated $338K.
  • Crossmark Global Holdings first reported a position in Procept Biorobotics in Q2 2022 and held it in 9 quarters.
  • Crossmark Global Holdings's Procept Biorobotics position peaked at $507K in Q4 2023.
  • 250 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2024.

Based on Crossmark Global Holdings's 13F filing for Q3 2024, filed 4 Nov 2024.